Patents by Inventor Michael B. Tyers
Michael B. Tyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5578632Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different represents a hydrogen atom or a C.sub.1-6 alkyl group;and physiologically acceptable salts and solvates thereof in combination with ranitidine, for the treatment of gastrointestinal dysfunction including the relief of nausea and vomiting, the promotion of gastric emptying, and the treatment of dyspepsia, reflux oesophagitis, flatulence, peptic ulcer, and gastric stasis.Type: GrantFiled: June 7, 1995Date of Patent: November 26, 1996Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5578628Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkynyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting.Type: GrantFiled: March 30, 1990Date of Patent: November 26, 1996Assignee: Glaxo Group LimitedInventors: Michael B. Tyers, Ian H. Coates, David C. Humber, George B. Ewan, James A. Bell
-
Patent number: 5482716Abstract: The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one or a physiologically acceptable salt or solvate thereof and dexamethasone or a physiologically acceptable salt or ester thereof. The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting.Type: GrantFiled: May 27, 1994Date of Patent: January 9, 1996Assignee: Glaxo Group LimitedInventors: Michael B. Tyers, Teresa E. Challoner
-
Patent number: 5420139Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of depression.Type: GrantFiled: August 16, 1993Date of Patent: May 30, 1995Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5411968Abstract: The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.Type: GrantFiled: January 14, 1993Date of Patent: May 2, 1995Assignee: Glaxo Group LimitedInventor: Michael B Tyers
-
Patent number: 5330982Abstract: The invention relates to the use of a compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors and promotes gastric emptying in conjunction with an H.sup.+ K.sup.+ ATPase inhibitor in the treatment of gastrointestinal disorders.Type: GrantFiled: August 25, 1992Date of Patent: July 19, 1994Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5298510Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.Type: GrantFiled: January 7, 1993Date of Patent: March 29, 1994Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5246941Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of depression.Type: GrantFiled: January 15, 1993Date of Patent: September 21, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5244909Abstract: The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.Type: GrantFiled: December 15, 1992Date of Patent: September 14, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5240954Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.Type: GrantFiled: December 9, 1991Date of Patent: August 31, 1993Assignee: Glaxo Group LimitedInventors: Michael B. Tyers, Ian H. Coates, David C. Humber, George B. Ewan, James A. Bell
-
Patent number: 5229407Abstract: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R.sup.Type: GrantFiled: July 10, 1992Date of Patent: July 20, 1993Assignee: Glaxo Group LimitedInventors: Ian H. Coates, Alexander W. Oxford, Peter C. North, Michael B. Tyers
-
Patent number: 5221687Abstract: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R4 is a hydrogen atom or a C.sub.Type: GrantFiled: August 25, 1992Date of Patent: June 22, 1993Assignee: Glaxo Group LimitedInventors: Ian H. Coates, Alexander W. Oxford, Peter C. North, Michael B. Tyers
-
Patent number: 5204356Abstract: The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.Type: GrantFiled: January 29, 1992Date of Patent: April 20, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5200414Abstract: The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.Type: GrantFiled: July 27, 1992Date of Patent: April 6, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5198447Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.Type: GrantFiled: July 16, 1991Date of Patent: March 30, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5190954Abstract: The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.Type: GrantFiled: October 20, 1989Date of Patent: March 2, 1993Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 5071854Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of depression.Type: GrantFiled: October 26, 1989Date of Patent: December 10, 1991Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 4985437Abstract: The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.Type: GrantFiled: December 16, 1987Date of Patent: January 15, 1991Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 4975436Abstract: The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.Type: GrantFiled: October 11, 1989Date of Patent: December 4, 1990Assignee: Glaxo Group LimitedInventor: Michael B. Tyers
-
Patent number: 4973594Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of depression.Type: GrantFiled: December 16, 1987Date of Patent: November 27, 1990Assignee: Glaxo Group LimitedInventor: Michael B. Tyers